A first-in-human Phase 1/2a study reported partial responses from a B7-H4-targeting antibody-drug conjugate in heavily pretreated ovarian, endometrial, and breast cancer patients. The early readout supports biological activity in a target that has been gaining attention in oncology. The trial’s framing is straightforward: efficacy signals were reported alongside safety experience typical for early ADC development, though the data remain limited by the small cohort size and pre-established Phase 1/2a structure. For biotech pipeline watchers, this is another example of ADC expansion into new surface antigens, where differentiation may hinge on payload choice, bystander effects, and tolerability patterns across tumor types.